The global immunology biosimilars market size is accounted at USD 11.23 billion in 2025 and is forecasted to hit around USD 49.61 billion by 2034, representing a CAGR of 17.95% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Immunology Biosimilars Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Immunology Biosimilars Market Revenue and Volume, By Disease
8.1.1 Inflammatory Bowel Disease
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Arthritis
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast
9.1. Immunology Biosimilars Market Revenue and Volume, By Distribution Channel
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Volume Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Disease
10.1.2. Market Revenue and Volume Forecast, By Distribution Channel
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Disease
10.1.3.2. Market Revenue and Volume Forecast, By Distribution Channel
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Disease
10.1.4.2. Market Revenue and Volume Forecast, By Distribution Channel
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Disease
10.2.2. Market Revenue and Volume Forecast, By Distribution Channel
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Disease
10.2.3.2. Market Revenue and Volume Forecast, By Distribution Channel
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Disease
10.2.4.2. Market Revenue and Volume Forecast, By Distribution Channel
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Disease
10.2.5.2. Market Revenue and Volume Forecast, By Distribution Channel
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Disease
10.2.6.2. Market Revenue and Volume Forecast, By Distribution Channel
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Disease
10.3.2. Market Revenue and Volume Forecast, By Distribution Channel
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Disease
10.3.3.2. Market Revenue and Volume Forecast, By Distribution Channel
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Disease
10.3.4.2. Market Revenue and Volume Forecast, By Distribution Channel
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Disease
10.3.5.2. Market Revenue and Volume Forecast, By Distribution Channel
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Disease
10.3.6.2. Market Revenue and Volume Forecast, By Distribution Channel
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Disease
10.4.2. Market Revenue and Volume Forecast, By Distribution Channel
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Disease
10.4.3.2. Market Revenue and Volume Forecast, By Distribution Channel
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Disease
10.4.4.2. Market Revenue and Volume Forecast, By Distribution Channel
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Disease
10.4.5.2. Market Revenue and Volume Forecast, By Distribution Channel
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Disease
10.4.6.2. Market Revenue and Volume Forecast, By Distribution Channel
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Disease
10.5.2. Market Revenue and Volume Forecast, By Distribution Channel
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Disease
10.5.3.2. Market Revenue and Volume Forecast, By Distribution Channel
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Disease
10.5.4.2. Market Revenue and Volume Forecast, By Distribution Channel
11.1. Novartis AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Mylan N.V.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AbbVie Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. STADA Arzneimittel AG
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Celltrion, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. KBI Biopharma, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Amgen, Inc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample